With 2024 as the year when the AOM market took shape, and 2026 a pivotal year that will define future competitive dynamics as the next wave of AOMs launch, and when the first off patent semaglutide likely becomes available in some countries, it is easy to dismiss 2025 as an uneventful transition
The answer is no, and it's not trying to
55 ENDOSCOPIC ABLATION Circumferential or focal RFA is performed 56 and then repeated after 34 months if there is residual intestinal metaplasia
They tell themselves they wont go through it the same way
Decreasing fluid retention, a common culprit behind under-eye puffiness, by promoting healthier cellular activity
So far, clinical trials havent resulted in regulatory approval, and pharmaceutical companies havent been motivated to invest in further development